The locally acting glucocorticosteroid budesonide enhances intestinal sugar uptake following intestinal resection in rats


Background and aims: Locally and systemically acting corticosteroids alter the morphology and transport function of the intestine. This study was undertaken to assess the effect of budesonide, prednisone, and dexamethasone on sugar uptake.

Methods: Adult male Sprague Dawley rats underwent transection or resection of 50% of the middle portion of the small intestine, and in vitro uptake of sugars was measured.

Results: The 50% enterectomy did not alter jejunal or ileal uptake of glucose or fructose. Prednisone had no effect on the uptake of glucose or fructose in resected animals. In contrast, in resected rats budesonide increased by over 120% the value of the jejunal maximal transport rate for the uptake of glucose, and increased by over 150% ileal uptake of fructose. Protein abundance and mRNA expression of the sodium dependent glucose transporter in brush border membrane (SGLT1), sodium independent fructose transporter in the brush border membrane (GLUT5), sodium dependent glucose and fructose transporter in the basolateral and brush border membranes (GLUT2), and Na+/K+ ATPase a1 and b1 did not explain the enhancing effect of budesonide on glucose or fructose uptake. Budesonide, prednisone, and dexamethasone reduced jejunal expression of the early response gene c-jun. In resected animals, expression of the mRNA of ornithine decarboxylase (ODC) in the jejunum was reduced, and corticosteroids reduced jejunal expression of the mRNA of proglucagon.

Conclusions: These data suggest that the influence of corticosteroids on sugar uptake in resected animals may be achieved by post translational processes involving signalling with c-jun, ODC, and proglucagon, or other as yet unknown signals. It remains to be determined whether budesonide may be useful to stimulate the absorption of sugars following intestinal resection in humans.

METHODS
Animals and diet
The principles for the care and use of laboratory animals approved by the Canadian Council on Animal Care and by the Council of the American Physiological Society were carefully followed.

Abbreviations: BMM, brush border membrane; BLM, basolateral membrane; ERG, early response genes; GLUT5, sodium independent fructose transporter in brush border membrane; GLUT2, sodium independent glucose and fructose transporter in the basolateral and brush border membranes; HRP, horseradish peroxidase; Km, apparent Michaelis constant; ODC, ornithine decarboxylase; SGLT1, sodium dependent glucose transporter in brush border membrane; TTBS, Tween Tris buffered saline; Vmax, maximal transport rate.
observed. Male pairs of Sprague Dawley rats were obtained from the University of Alberta Vivarium. Animals were housed in pairs at 21°C, with 12 hours of light and 12 hours of darkness. They weighed 200–250 g. Water and food were supplied ad libitum. Animals were fed standard Purina rat chow for two weeks.

**Drugs**

The glucocorticosteroids (budesonide, prednisone, and dexamethasone) were given to animals with a 50% resection. There were six animals in each of four treatment groups: control vehicle (0.19% EDTA buffered saline), budesonide (0.25 mg/kg body weight per day), prednisone (0.75 mg/kg body weight/day), and dexamethasone (128 µg/kg body weight/day). This dose of budesonide has been shown to modify intestinal absorption of nutrients in young animals with an intact intestine and fed chow39 and is similar to doses (0.2–0.8 mg/kg/day) used to treat trinitrobenzene sulfonic acid ileitis in rats40 and prevent graft rejection (0.1–1.0 mg/kg/day) in a rat model of intestinal transplantation.41 The control vehicle, budesonide, and prednisone were administrated by oral gavage and were dissolved in 0.19% EDTA buffered saline. Dexamethasone was administrated subcutaneously and was dissolved in bacteriostatic 0.9% sodium chloride solution. The volume of vehicle given was 5 µl/g body weight. Dosing was performed at 12:00 daily for two weeks, including weekends.

**Surgical model**

Rats were exposed to halothane (5.0%) until limp, when the hair on the anterior abdominal wall was clipped and the skin was cleansed with betadine. Animals were kept sedated under halothane (0.5–1.5%) throughout surgery. The sleeping animal was restrained in the supine position on an animal operating board using rubber band leg loops. A heating pad was maintained at 37°C under the operating board, with circulating water from a water bath during all subsequent surgical procedures. Following a ventral incision along the linea alba, the middle 50% of the small intestine was removed from half of the animals. The other half of the rats had a transection—that is, the small intestine was divided and then reanastomosed—without removal of any portion of the intestine. Sterile instruments and an aseptic technique were used. The colon was located, and the distance from the ileocaecal valve to the ligament of Treitz was measured with 5-0 silk string. The string was cut in half to give the approximate measure of the length of intestine to be resected. The intestinal portion to be resected was determined by placing one end of the measuring string at 2 cm after the ileal-caecal valve (to prevent back flow of bacteria from the colon), and working the string along the intestine towards the jejunal end. In resected animals, 50% of the middle portion of the intestine was removed, leaving the proximal 25% and the distal 25%. Bowel continuity was restored by an end to end jejunoileal anastomosis using interrupted 6-0 silk sutures. The abdomen was closed with a continuous 3.0 dexon suture. After surgery, animals received a subcutaneous injection of buprenorphine 0.01–0.05 mg/kg body weight for pain relief. Animals recovered in clean plastic cages under a heat lamp, and were then taken to fresh cages where they were housed individually.

**Table 1** Effect of steroids on the characteristics of the intestine of rats undergoing intestinal resection

<table>
<thead>
<tr>
<th>Site</th>
<th>Drug</th>
<th>Intestinal weight (mg/cm)</th>
<th>Intestinal wall comprised of mucosa (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jejunum</td>
<td>Control</td>
<td>23.4 (3.7)</td>
<td>47.5 (4.1)</td>
</tr>
<tr>
<td></td>
<td>Budesonide</td>
<td>23.1 (2.3)</td>
<td>48.7 (4.1)</td>
</tr>
<tr>
<td></td>
<td>Prednisone</td>
<td>24.2 (1.7)</td>
<td>48.5 (7.2)</td>
</tr>
<tr>
<td></td>
<td>Dexamethasone</td>
<td>21.1 (2.5)</td>
<td>64.2 (2.4)</td>
</tr>
<tr>
<td>Ileum</td>
<td>Control</td>
<td>17.5 (4.8)</td>
<td>52.8 (2.0)</td>
</tr>
<tr>
<td></td>
<td>Budesonide</td>
<td>14.5 (0.7)</td>
<td>40.4 (4.0)</td>
</tr>
<tr>
<td></td>
<td>Prednisone</td>
<td>13.5 (1.7)</td>
<td>52.2 (2.0)</td>
</tr>
<tr>
<td></td>
<td>Dexamethasone</td>
<td>9.4 (1.8)</td>
<td>52.2 (2.1)</td>
</tr>
</tbody>
</table>

Values are mean (SEM); n=6.

None of the differences was statistically significant.

**Table 2** Effect of corticosteroids on the value of the maximal transport rate (Vmax) and the Michaelis affinity constant (Km) of D-glucose in the jejunum and ileum of rats undergoing intestinal resection

<table>
<thead>
<tr>
<th>Drug</th>
<th>Jejunum Vmax (nmol×100 mg/tissue/min)</th>
<th>Jejunum Km (mM)</th>
<th>Ileum Vmax (nmol×100 mg/tissue/min)</th>
<th>Ileum Km (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>3066 (217)</td>
<td>39.7 (5.5)</td>
<td>2726 (320)</td>
<td>59.7 (11.9)</td>
</tr>
<tr>
<td>Budesonide</td>
<td>6790 (803)†</td>
<td>93.7 (16.5)†</td>
<td>5091 (964)</td>
<td>131.1 (34.0)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>2531 (533)†</td>
<td>35.7 (15.2)†</td>
<td>9354 (3313)</td>
<td>239.3 (102.8)</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>2991 (283)†</td>
<td>39.3 (7.3)†</td>
<td>5062 (2464)</td>
<td>118.3 (80.7)</td>
</tr>
</tbody>
</table>

Values are mean (SEM); n=6.

Vmax (maximal transport rate) is given in nmol×100 mg/tissue/min. Km (Michaelis affinity constant) is given in mM.

*p<0.05, budesonide, prednisone, or dexamethasone versus control; †p<0.05, prednisone or dexamethasone versus budesonide.
Tissue preparation and determination of uptake rates

Uptake studies were performed two weeks after small bowel transection or resection. Animals were anaesthetised by intraperitoneal injection of Euthanyl (sodium pentobarbitol) 240 mg/100 g body weight. The whole length of the transected small intestine or small intestine remaining after enterectomy was removed quickly. The intestine was everted and cut into small rings of approximately 2–4 mm each.

These rings were immersed immediately in preincubation beakers containing oxygenated Krebs bicarbonate buffer (pH 7.2) at 37°C and were allowed to equilibrate for approximately five minutes prior to commencement of the uptake studies. Uptake was initiated by the timed transfer of tissue rings to a solution containing [14C]-fructose concentration and uptake, values of Vmax and Km were estimated for each group were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using a modification of the method developed by Laemmli (1970). After migration, proteins were immobilised on a solid support by electroblotting to a nitrocellulose membrane. Then, membranes were blocked by incubation overnight in bovine lipo transfer technique optimiser (BLOTTO) containing 5% w/v dry milk in Tween Tris buffered saline (TTBS: 0.5% Tween 20, 30 mM Tris, 150 mM NaCl).

Western immunoblotting

BLM and BBM proteins from at least three animals in each group were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using a modification of the method developed by Laemmli (1970). After migration, proteins were immobilised on a solid support by electroblotting to a nitrocellulose membrane. Then, membranes were blocked by incubation overnight in bovine lipo transfer technique optimiser (BLOTTO) containing 5% w/v dry milk in Tween Tris buffered saline (TTBS: 0.5% Tween 20, 30 mM Tris, 150 mM NaCl).

Table 3  Effect of corticosteroids on the rate of uptake of d-fructose in rats undergoing intestinal resection

<table>
<thead>
<tr>
<th>Drug</th>
<th>Jejunum</th>
<th>Ileum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>31.9 (1.5)</td>
<td>26.5 (2.8)</td>
</tr>
<tr>
<td>Budesonide</td>
<td>30.4 (2.3)</td>
<td>45.0 (3.8)*</td>
</tr>
<tr>
<td>Prednisone</td>
<td>33.5 (2.3)</td>
<td>27.3 (1.9)*</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>23.3 (1.4)**</td>
<td>23.2 (1.5)*</td>
</tr>
</tbody>
</table>

Values are mean (SEM); n=6.

Rates of uptake of d-fructose are expressed as nmol/100 mg tissue/min. This represents the slope of the linear relationship between fructose concentration and uptake.

* p<0.05, budesonide, prednisone, or dexamethasone versus control;
† p<0.05, prednisone or dexamethasone versus budesonide;
‡ p<0.05, dexamethasone versus prednisone.

Membranes were washed three times with TTBS for at least 10 minutes. Then, membranes were probed with specific rabbit antirat antibodies that bound specifically to the antigens of interest. Incubation was carried out at room temperature for two hours for α1 Na+/K+ ATPase, β1 Na+/K+ ATPase, GLUT2, and GLUT5, and overnight for SGLT1. Antibodies were diluted in 2% dry milk in TTBS at 1:500 for α1 Na+/K+ ATPase, β1 Na+/K+ ATPase, GLUT2, GLUT5, and SGLT1, and at 1:2000 for β1 Na+/K+ ATPase.

Polyclonal antibodies against SGLT1 and GLUT2 were obtained from Biogenesis (Poole, UK). Polyclonal antibody against GLUT5 was obtained from Chemicon International Inc. (Temecula, California, USA). The polyclonal antibodies against α1 Na+/K+ ATPase, GLUT1, and GLUT2 were obtained from Upstate Biotechnology Inc. (Lake Placid, NY, USA).

Following this primary incubation, BBM and BLM were washed three times with TTBS to remove residual unbound primary antibody. Membranes were then incubated for one hour with goat antirabbit antibody, conjugated with horseradish peroxidase (HRP) (Pierce, Rockfort, Illinois, USA) that bound the primary antibody. This second antibody was diluted in 1:20 000 in 2% dry milk in TTBS.

After three washes in TTBS to remove residual secondary antibody, membranes were incubated for five minutes with SuperSignal chemiluminescent-HRP substrate (Pierce) composed of 50% stable peroxide solution and 50% luminol/enhancer solution. This reacted with the secondary antibody and made visible the antigens of interest. Then, membranes were exposed to X-Omat AR films for various times, and were successively plunged into developer, water, and fixer. Relative band densities were determined by transmittance densitometry using a Bio-Rad imaging densitometer (Life Science Group, Cleveland, Ohio, USA).

Northern immunoblotting

Complementary DNA (cDNA) probes were produced. Bacteria (Escherichia coli) were transformed with plasmids containing the desired DNA sequences to be used to probe for northern blotting. SGLT1 cDNA probe was donated by Dr Davidson (University of Chicago, Chicago, Illinois, USA); cDNA probes encoding the α1 and β1 Na+/K+ ATPase subunit isoforms were

Figure 1  (A) Effect of intestinal resection on ileal abundance of SGLT1 and the Na+/K+ ATPase α1 subunits. (B) Effect of intestinal resection on jejunal mRNA expression of Na+/K+ ATPase α1. Values are mean (SD). SGLT1, sodium dependent glucose transporter in brush border membrane; Alpha 1, Na+/K+ ATPase α subunit in the basolateral membrane; R, resection; T, transected.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Jejunum</th>
<th>Ileum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>23.3 (1.4)**</td>
<td>23.2 (1.5)*</td>
</tr>
<tr>
<td>Prednisone</td>
<td>33.5 (2.3)</td>
<td>27.3 (1.9)*</td>
</tr>
<tr>
<td>Budesonide</td>
<td>30.4 (2.3)</td>
<td>45.0 (3.8)*</td>
</tr>
</tbody>
</table>

Values are mean (SEM); n=6.

Rates of uptake of d-fructose are expressed as nmol/100 mg tissue/min. This represents the slope of the linear relationship between fructose concentration and uptake.

* p<0.05, budesonide, prednisone, or dexamethasone versus control;
† p<0.05, prednisone or dexamethasone versus budesonide;
‡ p<0.05, dexamethasone versus prednisone.
Figure 2  Effect of corticosteroids on abundance of SGLT1 and Na+/K+ ATPase α1 and β1 subunits. Values are mean (SD). SGLT1, sodium dependent glucose transporter in brush border membrane; Alpha 1, Na+/K+ ATPase α subunit in the basolateral membrane; Beta 1, Na+/K+ ATPase β subunit in the basolateral membrane. C, control; B, budesonide; P, prednisone; D, dexamethasone. Ratio of treatment (glucocorticosteroids) versus control animals. n=sample size. *p<0.05, budesonide, prednisone, or dexamethasone versus control; †p<0.05, prednisone or dexamethasone versus budesonide; ‡p<0.05, dexamethasone versus prednisone.

Figure 3  (A) Effect of intestinal resection on jejunal mRNA expression of GLUT5. (B) Effect of corticosteroids on jejunal mRNA expression of GLUT5 of rats undergoing intestinal resection. Values are mean (SD). n=sample size. GLUT5, sodium independent fructose transporter in the brush border membrane. In (A), R=resection, T=transected. Ratio of resected versus transected animals. *p<0.05, resected versus transected. In (B) C=control, B=budesonide, P=prednisone and D=dexamethasone. Ratio of treatment (glucocorticosteroids) versus control animals. *p<0.05, budesonide, prednisone, or dexamethasone versus control; †p<0.05, prednisone or dexamethasone versus budesonide; ‡p<0.05, dexamethasone versus prednisone.

RESULTS

Animal characteristics

Body weight gain, food intake, and weight gain (g/day) per food intake (g/day) were similar in transected and resected rats (data not shown). Dexamethasone reduced body weight gain in resected animals (from 4.8 g/day in controls to 2.0 g/day in those given dexamethasone) whereas budesonide and prednisone had no such effect. None of the steroids influenced food intake.

The total weight of the intestine and the percentage of the intestinal wall comprised of scrapable mucosa were similar in the jejunum and ileum of resected and transected rats (data not shown). Similarly, in resected rats budesonide, prednisone, or dexamethasone had no effect on the weight of the intestine or on the percentage of the intestinal wall comprised of mucosa (table 1). For this reason, the rates of sugar uptake were expressed on the basis of intestinal weight (nmol×100 mg/tissue/min).

Transporter activities

There was no effect of resection of the middle half of the intestine on values of maximal transport rate (Vmax) and
apparent Michaelis constant (Km) for jejunal or ileal uptake of glucose (data not shown). However, values of Vmax and Km for jejunal uptake of glucose were both approximately 120% higher in rats given budesonide compared with control vehicle (table 2). Values of Vmax and Km for jejunal uptake of glucose in resected rats were lower in those given prednisone or dexamethasone compared with budesonide. None of the corticosteroids had an effect on Vmax or Km for ileal uptake of glucose. Resection had no effect on the rates of jejunal and ileal uptake of L-glucose. Similarly, corticosteroids had no effect on L-glucose uptake into the jejunum (data not shown).

Resection had no effect on uptake of fructose into the jejunum or ileum (data not shown). In the jejunum of resected rats, dexamethasone reduced uptake of fructose by approximately 27% compared with control vehicle, budesonide, or prednisone (table 3). In the ileum of resected rats, budesonide increased the uptake of fructose by 100% compared with control vehicle, prednisone, or dexamethasone.

Transporter protein abundance and expression of mRNA

Protein abundance SGLT1 and Na⁺/K⁺ ATPase α₁ and β₁ in the jejunum was not altered by intestinal resection. However, in the ileum, abundance of SGLT1 was increased by resection whereas Na⁺/K⁺ ATPase α₂ was reduced and Na⁺/K⁺ ATPase β₁ was unchanged. Resection did not change jejunal or ileal mRNA expression of SGLT1 or Na⁺/K⁺ ATPase α₁ mRNA expression in the ileum was reduced by resection in the ileum (fig 1A). In the ileum, budesonide and dexamethasone increased the abundance of Na⁺/K⁺ ATPase β₁ compared with the control vehicle and prednisone group. In animals with resection, corticosteroids had no effect on mRNA expression of SGLT1 or Na⁺/K⁺ ATPase in the jejunum and ileum (fig 1B). Budesonide, prednisone, or dexamethasone administered to resected animals did not change jejunal abundance of SGLT1, or either of the Na⁺/K⁺ ATPase subunits (fig 2).

Resection did not have any significant effect on the abundance of GLUT5 or GLUT2 (data not shown). Expression of GLUT5 mRNA was reduced in the jejunum of resected compared with transected animals, and was unchanged in the ileum (fig 3A). GLUT5 mRNA was unchanged with resection. Corticosteroids did not affect the protein abundance of either GLUT5 or GLUT2 (data not shown). Prednisone increased mRNA expression of GLUT5 in the jejunum of resected animals compared with transected controls (fig 3B). Expression of GLUT5 mRNA in the ileum, and GLUT2 mRNA in either the jejunum and ileum, were unchanged by administration of corticosteroid.

Early response gene expression

Animals undergoing intestinal resection showed no differences in expression of mRNAs for c-myc or c-jun compared with those who underwent transection (data not shown).
Budesonide, prednisone, and dexamethasone reduced jejunal expression of the mRNA of c-jun in resected animals (table 4). No differences were observed in jejunal expression of c-myc or ileal expression of c-myc and c-jun.

**Proglucagon and ODC expression**

Expression in the jejunum and ileum of mRNA for proglucagon was not changed by resection. However, ODC expression in the jejunum of resected animals was reduced (table 5). No changes in ileal expression of the mRNA for ODC were observed. Corticosteroids reduced jejunal expression of the mRNA for proglucagon in resected animals compared with control vehicle but did not change ileal expression. Corticosteroids had no effect on jejunal or ileal expression of mRNA for ODC (table 6).

**DISCUSSION**

We chose a protocol of non-massive intestinal resection (50%) where the remaining proximal and distal intestinal remnants were adequate to assess the morphology and function at these sites.42 This 50% resection did not result in body weight loss, and is closer to the more common clinical situation seen for example in patients with Crohn's disease. In this study, the animals' food intake, body weight gain, intestinal weight, and percentage of intestinal weight comprised of mucosa were unaffected by intestinal resection. Thus the alterations in the function of the non-resected intestine in animals given steroids were not due to changes in these end points.

Intestinal absorption of nutrients is subject to adaptation of mediated and non-mediated processes, with alterations in transport influenced by the animal's age, diet, as well as by pathological processes such as diabetes mellitus, chronic ethanol intake, and abdominal irradiation.43 44 Following intestinal resection, morphological and functional changes occur depending on the extent of the intestine removed, the site studied, and the lipid content of the diet.45 Signals for this process are unknown but may include proglucagon derived peptides, ERGs, and ODC.46 47 48 49 ERGs such as c-myc, c-jun, and c-fos have been demonstrated to be involved in processes of intestinal proliferation and differentiation, as also is ODC, a key enzyme in the synthesis of polyamines which are a requirement in any proliferative event.50 Proglucagon also contributes to the intestinal adaptive process.51 52 For example, administration of short chain fatty acids increases proglucagon mRNA expression in rats undergoing intestinal resection.53 In this study, the adaptive response to intestinal resection did not change expression of the mRNAs for ERGs or proglucagon but ODC mRNA was reduced in the jejunum of resected rats. Adaptation in sugar absorption following intestinal resection must involve other signals. Epi morphin/syntaxin 2 mRNA that codes for a membrane associated protein involved in morphogenesis of the lungs and skin, and PC4/TIS7, a gene involved in nerve growth factor mediated cytidifferentiation, may be among other signals that might be involved in the adaptive response after intestinal resection.54 55 New signals involved in the adaptive intestinal response after resection have recently been identified by cDNA microarray analysis.17 18

Glucocorticosteroids are used to treat patients with a variety of intestinal conditions, including Crohn's disease and ulcerative colitis. Clinical studies have focused on the use of the potent locally acting steroid, budesonide.56 57 Prednisone and budesonide modify the morphology and absorptive function of the intestine in young rats with an intact intestinal tract.19 Corticosteroids may have metabolic (for example, glutamine) and/or functional (for example, electrolyte transport) actions that could explain effects on intestinal absorption. Furthermore, the effect of glucocorticosteroids on cell renewal rate and apoptosis as well as central effects could also in principle alter gut function.15 16 17 18 This study compared the influence of the locally active budesonide with two systemically active corticosteroids (prednisone given by mouth and dexamethasone given by subcutaneous injection) in 12 animals in which a portion of the jejunum and ileum remained after removal of the middle half of the small intestine.

Although we used the same dose of dexamethasone (128 µg/kg subcutaneously) which has been reported previously to blunt the expected increase in the bowel content of DNA one week after an 80% enterectomy,40 we were unable to demonstrate any adverse effect of dexamethasone on the weight of the jejunum or ileum of 50% resected animals. This lack of detrimental effect of dexamethasone may have been due to differences in animal strain, their age, length of intestine resected (50% vs 80% ileum), time after surgery, and experimental parameters were performed, or total dose of dexamethasone used. In resected animals, neither budesonide nor prednisone altered the weight of the intestine, or the percentage of the intestinal wall comprised of mucosa. It is possible that had we subjected the animals to a massive bowel resection (80% of the small bowel removed), the weight of the remaining intestine per unit length or surface area might have increased. None the less, based on these data, two weeks following a 50% enterectomy, it is clear that these corticosteroids given in these doses and by these routes had no adverse effects on the weight of the intestine. Thus the data suggest that the effects of corticosteroids on the absorptive functions of the intestine, to be discussed, were not due to any corticosteroid induced change in the mass of the intestine.

While absorption of some nutrients may be increased after intestinal resection, the magnitude of this effect depends on the extent of resection, site and time after surgery when uptake experiments are performed, as well as the manner of the expression of the data.7 35 36 With removal of the middle half of the small intestine in this study, there was no change in the uptake of D-glucose (table 2), L-glucose, or D-fructose (data not shown) compared with transected animals. We could have subjected the animals to a massive small bowel resection and potentially been able to show enhanced uptake of sugars. However, interpretation of the results would then have been more difficult because of the expected concomitant changes in food intake, body weight gain, and intestinal weight. Furthermore, we wished these studies to have some potential clinical relevance. For example, in patients with Crohn's disease, prednisone or budesonide may be used therapeutically in doses similar to those used in this study, and while many of these individuals may have previously undergone an intestinal resection, massive resections would be unusual.

The doses of prednisone and budesonide used in this study were chosen on the basis of regimens which have been shown to be clinically useful in humans.17 18 19 The dose used has been shown to modify intestinal absorption of fructose and some lipids in chow fed rats with an intact intestine.23 There is a difference in the potency of various corticosteroids on absorption of sugars after a 50% enterectomy; prednisone had no influence on the Vmax of glucose uptake or on uptake of fructose whereas budesonide increased by over 120% the value of Vmax (table 2). Also, budesonide increased by 70% ileal uptake of fructose (table 3). This occurred without any change in the non-mediated passive component of sugar uptake, as measured with t-glucose. Thus the locally active steroid budesonide accelerated intestinal absorption of these two sugars following intestinal resection.

Carrier mediated uptake is usually characterised by two kinetic constants: the maximal transport rate (Vmax) and Michaelis-Menten constant (Km) that corresponds to that concentration of solute that will give one half Vmax and represents the solute binding affinity. Our findings showed a change in Vmax and Km for glucose uptake (table 2) suggesting that the number of transporters per enterocyte increases, and the
characteristics of the protein may change also. For this reason we proceeded and performed western and northern blots, as discussed below. Other possibilities that could explain the findings in Vmax and Km are also considered.

Protein abundance and mRNA expression of the transporters responsible for BBM uptake of glucose and fructose (SGLT1 and GLUT5, respectively) did not correlate with changes in the activity of these transporters. For instance, enhanced jejunal glucose uptake with budesonide (table 2) was not accompanied by an increase in the abundance of SGLT1 or its mRNA. Also, enhanced fructose uptake with budesonide in the ileum (table 3) was not accompanied by changes in GLUT5 abundance or mRNA expression. The reason for having only three animals in some of the studies was due to the fact that the uptake studies required a large and uniform amount of tissue (n=6), and there was not always sufficient amounts of tissue left to be able to perform larger numbers of the western and northern blots. Therefore, our negative results should be carefully considered, and we cannot discard the possibility that there were small changes in gene expression which we were unable to demonstrate given the small sample size. We did not perform immunohistochemistry of SGLT1 or GLUT5 and therefore it is possible that corticosteroids may modify sugar uptake by changing the distribution of these transporters along the villus, thereby increasing uptake without any variation in the total abundance of transporters. Also, Kellett et al have provided evidence to suggest that under some circumstances when the activity of SGLT1 is stimulated, the increased cytosolic levels of protein kinase CβII facilitate trafficking of GLUT2 to the BBM thereby providing an additional transporter for glucose and fructose.α1,α2,15 Thus it is possible that a post-translational event is involved in the regulation of sugar uptake in response to administration of corticosteroids.

Although the systemic bioavailability of budesonide is approximately one order of magnitude lower than that for prednisone, its potency is much higher.α1,α2,15,α6,17 We speculate that the stimulatory effect of budesonide on the jejunal uptake of glucose by SGLT1 and ileal uptake of fructose by GLUT5 is the result of its greater effect on the enteroocyte receptors for glucocorticosteroids. This adaptive response with budesonide following intestinal resection may be important to maintain the well being of the animal. The glucose and fructose absorption promoting effect of budesonide following intestinal resection may prove to be a useful agent to enhance the intestinal adaptive response.

ACKNOWLEDGEMENTS

The authors wish to thank Kim Doring, Rob Drummond, Elizabeth Jarocka-Cyta, Daphne Samuel, Elizabeth Wierzbicki, Mika Wierzbicki, and Muriel Guelly for their help and technical assistance. The financial support of the Medical Research Council of Canada and of AstraZeneca Inc (former Astra Pharm Inc.) was greatly appreciated. We thank Ciencia Laboratorio Medico (Brasil) and CAPES for the support of Dr Aducio Thiesen. Dr MT Clandinin wishes to acknowledge the generous support of the National Science and Engineering Research Council of Canada. Dr G Wild is a research scholar of Les Fonds de la Recherche en Sante du Quebec

Edmonton, Canada

All authors are members of the Cell and Molecular Biology Collaborative Network in Gastrointestinal Physiology

REFERENCES


www.gutjnl.com

Gut: first published as 10.1136/gut.52.2.252 on 1 February 2003. Downloaded from http://gut.bmj.com/ on March 3, 2022 by guest. Protected by copyright.
49 Warner BW. GP2 as therapy for the short bowel syndrome. Gastroenterology 2001;120:1041–2.